雅培进军仿制药市场的背后 仿制药市场必争 并购扩张务实

The Background for Abbot to Tap into Generic Market

仿制药市场这个诸多跨国公司的必争之地,雅培也没有放过。近日,雅培出资37.2亿美元收购了印度Piramal Healthcare公司旗下的仿制药部门。此举将会拓展雅培在仿制药领域以及新兴市场印度的业务,增强了雅培的市场竞争力。

Generic market is a place of strategic importance for multinational pharmaceutical companies. Abbott acquired India's Piramal Healthcare's generics business for $3.7 bln in May. The acquisition marks a major push into generic market and the healthcare market in the emerging countries by the brand drugmaker, and improves the competitiveness of Abbott.